RxDoctor Payments DataLook up a doctor →

Vishala Chindalore, MD

Rheumatology · Anniston, ALNPI 1083635015

Payments from drug & device makers

$3,476,633in general payments, 2019–2025

Across 1,767 payments — averaging $1967.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$899K
  • Novartis$677K
  • Hoffmann-la Roche Limited$462K
  • Pfizer$313K
  • Eli Lilly$291K
  • GSK$221K
  • plus $612K from 52 others
$35,765in research payments, 2019–2025

Across 6 payments — averaging $5960.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$28K
  • Eli Lilly$7K
  • F. Hoffmann-la Roche AG$767

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)299$898,985
Novartis78$677,277
Hoffmann-la Roche Limited14$462,180
Pfizer155$313,338
Eli Lilly7$291,326
GSK136$221,050
AbbVie250$133,595
Janssen Research & Development, LLC8$86,569
F. Hoffmann-la Roche AG1$70,708
Daiichi Sankyo Company LTD14$59,920
Daiichi Sankyo Inc.131$56,073
Takeda Pharmaceuticals U.S.A., Inc.19$37,023
EMD Serono, Inc.10$34,388
Swedish Orphan Biovitrum AB3$24,070
Regeneron11$16,848
Roche Products Limited2$13,469
Kiniksa Pharmaceuticals, Ltd.56$11,853
AstraZeneca(2 entities)53$11,784
Biogen1$11,341
Sun Pharmaceutical Industries Inc.31$9,974
Kiniksa Pharmaceuticals International, PLC4$8,739
Noven Pharmaceuticals, Inc.9$6,788
E.r. Squibb & Sons, L.L.C.63$5,799
Johnson & Johnson(2 entities)107$4,070
Vertex2$2,569
UCB, Inc.133$1,998
Galt Pharmaceuticals, LLC2$1,471
Lilly USA, LLC44$690
Mallinckrodt Hospital Products Inc.20$550
ANI Pharmaceuticals, Inc.11$280
Genentech USA, Inc.14$224
Organon16$212
Aurinia Pharma U.S., Inc.6$142
Atland Pharmaceuticals, LLC1$125
Rigel Pharmaceuticals, Inc.1$125
Bristol Myers Squibb12$115
Sandoz6$101
Novo Nordisk1$98
Boehringer Ingelheim4$95
Xeris Pharmaceuticals, Inc.1$88
Fresenius Kabi USA, LLC5$84
Medexus Pharma, Inc.2$78
Radius Health, Inc.4$70
Sobi, Inc3$56
Hikma Pharmaceuticals USA3$48
Ultragenyx Pharmaceutical Inc.2$41
Mallinckrodt Enterprises LLC1$21
Exact Sciences1$20
Biohaven Pharmaceutical Holding Company Ltd.1$20
Scilex Pharmaceuticals Inc.1$18
Tonix Medicines, Inc.1$18
Zyla Life Sciences, Inc.1$17
PBG Puerto Rico LLC1$17
Bioventus LLC1$17
Sanofi Pasteur Inc.1$16
Eisai Inc.1$16
Merck1$14
Cumberland Pharmaceuticals, Inc.1$12

How this compares

$3,476,633 in reported general payments places this provider in the 95th percentile of 90 rheumatology providers in Alabama.

See all rheumatology providers in Alabama

Medicare billing

Part B allowed, 2024
$2,965,996
Medicare patients
833
Services billed
173,980

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other rheumatology in Anniston

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →